Anticoagulation is a critical component in the treatment of cardiovascular diseases. Large randomised controlled trials have ...

Systematic review shows GLP 1 receptor agonists trials rarely assess dietary intake, highlighting a major evidence gap in nutrition outcomes.

Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...

‘A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial’ by David Erritzoe et al. was published in Nature Medicine at 16:00 UK time on ...

An expert in Clinical Trials from the University of Nottingham is part of an international team of experts who have come together to enhance clinical ...

A digital pathology AI model to predict immune-oncology biomarker status and pembrolizumab response in a real-world cohort of patients with colorectal and breast cancer. Changes in non-small cell lung ...

Objective To compare the effects of aerobic training combined with muscle strength training (hereafter referred to as combined training) to aerobic training alone on cardiovascular disease risk ...

“Well, we don’t have as much evidence as we would like on steroid use during pregnancy,” the obstetrician warned my co-author, Natalia Emanuel, as she wrote a prescription for inhaled corticosteroids ...

With evidence from 85,373 participants across 11 trials, GLP-1 receptor agonists significantly reduced kidney failure risk and cardiovascular events, showing consistent benefits across diabetes and ...

1 Sports Orthopedic Research Center–Copenhagen (SORC-C), Arthroscopic Center, Department of Orthopedic Surgery, Copenhagen University Hospital, Amager-Hvidovre, Hvidovre, Denmark Objective To ...